24/7 Wall St. on MSN
Biotech could be one of 2026’s biggest winners, and this ETF is perfectly positioned
Quick Read FBT returned 29% over the past year and gained 5.4% in the first week of 2026. Federal Reserve officials forecast ...
Biotech Showcase™ Provides Private and Micro- to Mid-Cap Public Company Executives One-Stop Access to Investors, Pharma ...
After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...
Investor's Business Daily on MSN
Biotech stocks' dark winter is over. What that means for investors.
The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping ...
O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...
The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz (A16z). | The ...
1d
‘A little bit more certainty’: After shaky years, Mass. life science companies find glimmers of hope
As they prepare for the J.P. Morgan Healthcare Conference next week, biotech leaders and analysts say companies are better ...
The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).
A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...
Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback